BioLineRx (NASDAQ:BLRX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRXFree Report) in a report issued on Tuesday, Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock.

Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a report on Monday, December 4th.

View Our Latest Research Report on BioLineRx

BioLineRx Price Performance

Shares of NASDAQ BLRX opened at $1.03 on Tuesday. BioLineRx has a 1 year low of $0.79 and a 1 year high of $2.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.96 and a quick ratio of 1.86. The company’s 50-day moving average is $1.21 and its 200 day moving average is $1.47. The stock has a market capitalization of $74.61 million, a P/E ratio of -1.23 and a beta of 1.40.

Institutional Investors Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently bought and sold shares of BLRX. Renaissance Technologies LLC grew its holdings in BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 189,678 shares during the period. Atria Wealth Solutions Inc. bought a new position in shares of BioLineRx in the first quarter worth approximately $178,000. Envestnet Asset Management Inc. bought a new position in shares of BioLineRx in the first quarter worth approximately $88,000. LPL Financial LLC lifted its stake in shares of BioLineRx by 152.7% in the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after buying an additional 71,134 shares in the last quarter. Finally, PVG Asset Management Corp bought a new position in shares of BioLineRx in the fourth quarter worth approximately $97,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

(Get Free Report)

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

See Also

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.